CONTACT US

Taipei Headquarters

  • Address:
    7F., No. 21, Sec. 2, Chong Shan N. Rd., Chong Shan Dist., Taipei City 104404, Taiwan (R.O.C.)

  • Tel:
    +886-2-2542-6789

    FAX:
    +886-2-2561-6054

  • E-mail:
    contact@sanfubio.com.tw

Liuying Factory

  • Address:
    No. 1, Sec. 1, Huanyuan E. Rd., Liuying Dist., Tainan City 736006, Taiwan (R.O.C.)

  • Tel:
    +886-6-623-1822

    FAX:
    +886-6-623-1805

  • E-mail:
    michael@sfchem.com.tw

×

SFB101

First-in-Class novel drug in preclinical stage

What is a retinal disease?

The retina consists of millions of photoreceptor cells and other nerve cells responsible for receiving and organizing visual signals.1 Population-based studies show retinal diseases prevalence ranging from 5.35% to 21.02% in individuals aged 40 and above.2 Retinal diseases are the primary cause of irreversible blindness in developed countries and the second leading cause of blindness in developing countries, following cataracts.

Unmet Medical Needs

Anti-VEGF therapy reduces vision loss in wet macular degeneration and diabetic retinopathy. However, frequent intravitreal injections increase infection risk and burdens. Urgently needed are effective, patient-friendly drugs to prevent irreversible blindness.

Preclinical Stage

We are co-developing SFB101 with a national research institute in Taiwan, currently in the preclinical stage.

A novel drug candidate potential effective and patient-friendly treat the retinal diseases, preventing blindness.

  1. Richard H. Masland. Neuron. 2012; 76(2): 266-280.
  2. Matthew J Burton et al. Lancet Glob Health. 2021; 9(4): e489-e551.
×

SFB201

A First-in-class liposomal drug that effectively regulates the immune system's balance for prophylaxis against acute Graft-versus-Host Disease (aGvHD).

What is GvHD?

Many blood disorders, such as leukemia, require allogeneic hematopoietic stem cell transplantation (AHSCT) as a vital treatment option. However, graft-versus-host disease (GvHD), where immune cells from the donor attack the recipient's organs, remains a major and potentially fatal complication of AHSCT1.

The action of balancing the immune system.

SFB201 (originally named RGI-2001) is a new chemical entity (NCE) with liposomal formulation. The primary mechanism involves inducing an increase in regulatory T cells (Treg), initiating specific immune tolerance. These antigen-specific Tregs have been shown to downregulate the immune response directed toward specific antigens without causing generalized immunosuppression2.

Plan to enter Phase 3 clinical trial in 2024

The Phase 1/2a trial (NCT01379209)3 and the Phase 2b trial (NCT04014790)4in the USA has been completed. Planning to initiate a multi-center, multi-national Phase 3 clinical trial in the USA, Taiwan, and most likely, South Korea, in 2024.

SFB201 aims to enhance the success rate of AHSCT by preventing acute GvHD.

×

SFB202

×

SFB301